Chromosome 18 gene dosage map 2.0.

Area of Science:

• Genetics
• Genomic Medicine
• Clinical Genetics

Background:

• The first generation of chromosome 18 gene dosage maps was established in 2009.
• These maps annotated genes and phenotype-associated regions to aid in understanding the clinical impact of chromosomal alterations.
• Advances in understanding molecular mechanisms of genetic diseases necessitate map updates.

Purpose of the Study:

• To update and enhance the chromosome 18 gene dosage maps with recent data and improved classifications.
• To provide clinicians with a more accurate tool for assessing the clinical significance of chromosome 18 deletions and duplications.
• To introduce clinically oriented classifications reflecting the spectrum of pathogenicity.

Main Methods:

• Expansion of gene dosage maps to include specific maps for hemizygosity and suprazygosity.
• Revamping classification systems from mechanistic definitions to clinically oriented categories (e.g., risk factor, conditional, low penetrance, causal).
• Continuous updating of maps with the latest relevant data for chromosome 18.

Main Results:

• The Gene Dosage Map 2.0 now incorporates hemizygosity and suprazygosity maps.
• A new classification system provides a gradient from pathogenic to benign, better representing clinical reality.
• The updated maps offer a more nuanced understanding of gene dosage effects on chromosome 18.

Conclusions:

• The updated chromosome 18 gene dosage maps (Gene Dosage Map 2.0) provide enhanced clinical utility.
• The new classification system offers a more accurate representation of genetic variation impact.
• This model for chromosome 18 can potentially be applied to other genomic regions.